NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

先天性水皰症治療藥的全球市場:2019年∼2023年

Global Epidermolysis Bullosa Therapeutics Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 781917
出版日期 內容資訊 英文 128 Pages
訂單完成後即時交付
價格
先天性水皰症治療藥的全球市場:2019年∼2023年 Global Epidermolysis Bullosa Therapeutics Market 2019-2023
出版日期: 2019年01月17日內容資訊: 英文 128 Pages
簡介

儘管在過去幾十年進行了大量的研究活動,但尚未開發出副作用少的水疱性表皮鬆解症的有希望治療方法。因此,各種政府和私人組織正在釋放資金,以促進有前景的治療方法的研究,這些治療方法比現有的治療水疱性表皮鬆解症的藥物具有更好的安全性和療效。歐洲水疱性表皮鬆解症研究的資金也在增加。這種資金和資金支援有助於開發治療水疱性表皮鬆解症的新型治療藥物。Technavio的分析師預測,到2023年,水疱性表皮鬆解症治療市場的年複合成長率將接近5%。

本報告提供全球先天性水皰症治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 報告的範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • 抗生素
  • 止痛藥
  • 其他的治療藥物
  • 市場機會:各產品

第7章 客戶形勢

第8章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 成長要素與課題

  • 市場成長要素
  • 市場課題

第10章 市場趨勢

第11章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第12章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Amryt Pharma
  • Fresenius
  • Johnson & Johnson
  • Novartis
  • Pfizer

第13章 附錄

  • 調查方法
  • 簡稱的清單
目錄
Product Code: IRTNTR30680

About this market

Despite the significant research activities undertaken over the past several decades, a promising treatment with very few side effects is not yet developed for the treatment of epidermolysis bullosa. Hence, various government and private organizations are releasing funds to advance the research on the development of promising therapeutics that can demonstrate better safety and efficacy than the available medications for the treatment of epidermolysis bullosa. The funding for the research on epidermolysis bullosa in Europe is also increasing. Such funding and financial supports are helpful for the development of novel therapeutic drugs for the treatment of epidermolysis bullosa. Technavio's analysts have predicted that the epidermolysis bullosa therapeutics market will register a CAGR of almost 5% by 2023.

Market Overview

Rising awareness about epidermolysis bullosa

Epidermolysis bullosa is a group of inherited diseases in which the skin becomes very brittle and forms acute blisters after a minor injury or gentle friction. Therefore, to avoid the delay in the diagnosis and the unawareness of the treatment options, several government and non-government organizations are conducting various awareness programs.

Lack of approved therapeutics

The unavailability of approved therapeutics for the treatment of epidermolysis bullosa is expected to hamper the growth of the epidermolysis bullosa therapeutics market over the forecast period.

For the detailed list of factors that will drive and challenge the growth of the epidermolysis bullosa therapeutics market during the 2019-2023, view our report.view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Antibiotics - Market size and forecast 2018-2023
  • Analgesics - Market size and forecast 2018-2023
  • Other therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amryt Pharma
  • Fresenius
  • Johnson & Johnson
  • Novartis
  • Pfizer

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global rare diseases therapeutics market
  • Exhibit 03: Segments of global rare diseases therapeutics market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: Antibiotics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Antibiotics - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Analgesics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Analgesics - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Other therapeutics - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by product
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in North America
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in Europe
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Asia
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in ROW
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: Decision framework
  • Exhibit 44: Recent therapeutics that have received orphan drug designation from the US FDA
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Early phase developmental therapeutics for the treatment of epidermolysis bullosa
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Landscape disruption
  • Exhibit 49: Vendors covered
  • Exhibit 50: Vendor classification
  • Exhibit 51: Market positioning of vendors
  • Exhibit 52: Amryt Pharma - Vendor overview
  • Exhibit 53: Amryt Pharma - Business segments
  • Exhibit 54: Amryt Pharma - Organizational developments
  • Exhibit 55: Amryt Pharma - Geographic focus
  • Exhibit 56: Amryt Pharma - Segment focus
  • Exhibit 57: Amryt Pharma - Key offerings
  • Exhibit 58: Amryt Pharma - Key customers
  • Exhibit 59: Fresenius - Vendor overview
  • Exhibit 60: Fresenius - Business segments
  • Exhibit 61: Fresenius - Organizational developments
  • Exhibit 62: Fresenius - Geographic focus
  • Exhibit 63: Fresenius - Segment focus
  • Exhibit 64: Fresenius - Key offerings
  • Exhibit 65: Fresenius - Key customers
  • Exhibit 66: Johnson & Johnson - Vendor overview
  • Exhibit 67: Johnson & Johnson - Business segments
  • Exhibit 68: Johnson & Johnson - Organizational developments
  • Exhibit 69: Johnson & Johnson - Geographic focus
  • Exhibit 70: Johnson & Johnson - Segment focus
  • Exhibit 71: Johnson & Johnson - Key offerings
  • Exhibit 72: Johnson & Johnson - Key customers
  • Exhibit 73: Novartis - Vendor overview
  • Exhibit 74: Novartis - Business segments
  • Exhibit 75: Novartis - Organizational developments
  • Exhibit 76: Novartis - Geographic focus
  • Exhibit 77: Novartis - Segment focus
  • Exhibit 78: Novartis - Key offerings
  • Exhibit 79: Novartis - Key customers
  • Exhibit 80: Pfizer - Vendor overview
  • Exhibit 81: Pfizer - Business segments
  • Exhibit 82: Pfizer - Organizational developments
  • Exhibit 83: Pfizer - Geographic focus
  • Exhibit 84: Pfizer - Segment focus
  • Exhibit 85: Pfizer - Key offerings
  • Exhibit 86: Pfizer - Key customers
  • Exhibit 87: Validation techniques employed for market sizing
  • Exhibit 88: List of abbreviations